AbbVie
ABBV
₹16,163
Share price
-0.77%
Change (1 day)
15.75%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
EPS for AbbVie (ABBV)
EPS in 2025 (TTM): ₹198.43
According to AbbVie's latest financial reports the company's current EPS (TTM) is ₹201.31. In 2024 the company made an earnings per share (EPS) of ₹205.58 a decrease over its 2023 EPS that were of ₹234.66.
EPS history for AbbVie from 2013 to 2025
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2025 (TTM) | ₹198.43 | -3.48% |
| 2024 | ₹205.58 | -12.39% |
| 2023 | ₹234.66 | -58.95% |
| 2022 | ₹571.66 | 2.49% |
| 2021 | ₹557.77 | 121.58% |
| 2020 | ₹251.72 | -44.7% |
| 2019 | ₹455.18 | 45.84% |
| 2018 | ₹312.10 | 9.72% |
| 2017 | ₹284.46 | -9.54% |
| 2016 | ₹314.46 | 16.28% |
| 2015 | ₹270.43 | 184.1% |
| 2014 | ₹95.19 | -57.15% |
| 2013 | ₹222.14 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | ₹118.69 | -41.04% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | ₹228.85 | 13.68% | 🇺🇸 USA |
 Eli Lilly LLY | ₹1,055 | 424.11% | 🇺🇸 USA |
 Amgen AMGN | ₹943.56 | 368.71% | 🇺🇸 USA |
 Gilead Sciences GILD | ₹408.16 | 102.75% | 🇺🇸 USA |
 Biogen BIIB | ₹867.56 | 330.96% | 🇺🇸 USA |
 GlaxoSmithKline GSK | ₹133.19 | -33.84% | 🇬🇧 UK |
 AstraZeneca AZN | ₹213.90 | 6.25% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | ₹258.73 | 28.52% | 🇺🇸 USA |